Genovis AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0002485979
SEK
20.45
20.45 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Negative results in Jun 25

  • OPERATING CASH FLOW(Y) Lowest at SEK 24.57 MM
  • INTEREST(9M) At SEK 0.29 MM has Grown at 122.48%
  • NET PROFIT(HY) At SEK 8.57 MM has Grown at -41.01%
2

With ROE of 11.29%, it has a very expensive valuation with a 5.88 Price to Book Value

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,364 Million (Small Cap)

stock-summary
P/E

52.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.58

stock-summary
Return on Equity

8.04%

stock-summary
Price to Book

5.18

Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Icon
Company does not have enough history
Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
16.65%
EBIT Growth (5y)
85.46%
EBIT to Interest (avg)
26.63
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
0.63
Tax Ratio
35.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
46.73%
ROE (avg)
18.20%

Valuation key factors

Factor
Value
P/E Ratio
52
Industry P/E
Price to Book Value
5.88
EV to EBIT
48.58
EV to EBITDA
34.84
EV to Capital Employed
17.01
EV to Sales
10.15
PEG Ratio
0.93
Dividend Yield
NA
ROCE (Latest)
35.02%
ROE (Latest)
11.29%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -10.53% vs 15.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 45.71% vs -23.91% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28.90",
          "val2": "32.30",
          "chgp": "-10.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.20",
          "val2": "11.60",
          "chgp": "-37.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.10",
          "val2": "3.50",
          "chgp": "45.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "160.30%",
          "val2": "281.50%",
          "chgp": "-12.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.57% vs 54.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.50% vs 449.11% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "130.40",
          "val2": "158.20",
          "chgp": "-17.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.30",
          "val2": "63.70",
          "chgp": "-38.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "32.90",
          "val2": "61.50",
          "chgp": "-46.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "221.20%",
          "val2": "341.30%",
          "chgp": "-12.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary

Jun'25
Mar'25
Change(%)
Net Sales
28.90
32.30
-10.53%
Operating Profit (PBDIT) excl Other Income
7.20
11.60
-37.93%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
5.10
3.50
45.71%
Operating Profit Margin (Excl OI)
160.30%
281.50%
-12.12%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -10.53% vs 15.77% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 45.71% vs -23.91% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
130.40
158.20
-17.57%
Operating Profit (PBDIT) excl Other Income
39.30
63.70
-38.30%
Interest
4.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
32.90
61.50
-46.50%
Operating Profit Margin (Excl OI)
221.20%
341.30%
-12.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -17.57% vs 54.49% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.50% vs 449.11% in Dec 2023

stock-summaryCompany CV
About Genovis AB stock-summary
stock-summary
Genovis AB
Pharmaceuticals & Biotechnology
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Company Coordinates stock-summary
Company Details
Medicon Village, Scheelevagen 2 , LUND None : 223 63
stock-summary
Tel: 46 46 101230
stock-summary
Registrar Details